TNO155

Key Takeaways

• First allosteric SHP2 inhibitor to reach clinical trials
• Derived from 1.5 million compound HTS and SBDD
• Aimed to overcome phosphatase active‑site inhibitor limitations
• Program terminated for business reasons, not safety
• Novartis removed TNO155 from public pipeline

Pulse Analysis

SHP2 sits at a pivotal node of the RTK‑RAS‑MAPK cascade, translating growth‑factor signals into cellular proliferation. Because phosphatases lack deep active‑site pockets, traditional inhibitor design has struggled with potency and off‑target effects. Allosteric modulation—locking SHP2 in its autoinhibited state—offers a strategic workaround, promising higher selectivity and better pharmacokinetics. This approach has attracted significant interest from biotech firms seeking to exploit the RAS‑driven oncology market, where effective downstream blockade remains a high‑value objective.

Novartis’s TNO155 (batoprotafib) embodied this strategy. Leveraging a massive 1.5 million‑compound high‑throughput screen and subsequent structure‑based drug design, the team identified a molecule that could bind a cryptic pocket and stabilize SHP2’s inactive conformation. Early preclinical data demonstrated robust inhibition of downstream ERK signaling and favorable oral bioavailability, positioning TNO155 as a potential first‑in‑class therapy for advanced solid tumors. The program’s progression to Phase 1 underscored both the scientific feasibility of allosteric phosphatase inhibition and the commercial appetite for novel RAS‑pathway agents.

However, the project was halted for business reasons, not safety concerns, reflecting the steep cost and uncertain return of pioneering modalities. Novartis’s decision sends a cautionary signal to investors and developers: even promising mechanistic breakthroughs must align with portfolio priorities and market forecasts. The termination may redirect resources toward more mature targets or combination strategies, but it also leaves a gap that competitors could fill. Future allosteric phosphatase programs will likely emphasize clearer differentiation, robust biomarker strategies, and partnership models to mitigate financial risk while capitalizing on the therapeutic potential of SHP2 inhibition.